Kadimastem

Gamida Cell is an Israeli biotechnology company developing and commercializing stem-cell and cell therapies for patients with blood cancers and other serious hematologic disorders. Its product Omisirge (omidubicel-onlv), derived from cord blood, was approved in the United States to accelerate hematopoietic stem-cell recovery after transplantation in eligible patients with blood cancers.

Kang Stem Biotech Co., Ltd. is a South Korean biotechnology company located in Seoul that specializes in stem cell research and development.

Cynata Therapeutics is a biotechnology research company headquartered in Cremorne, Australia, focused on therapeutic products and stem cell technology.

Calidi Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on immuno-oncology, dedicated to developing advanced immunotherapies for various cancers. The company's innovative approach centers on utilizing powerful, allogeneic (donor-derived) stem cells as specialized carriers for anti-tumor agents. This technology is being advanced to address a range of oncological conditions, including aggressive brain tumors (high-grade gliomas) and other solid malignancies. Calidi's proprietary cell-based delivery systems are expertly designed to safeguard, amplify, and boost the therapeutic effects of oncolytic viruses. This strategic delivery method aims to achieve superior treatment efficacy and enhance patient safety. The company's clinical pipeline features two primary candidates: NeuroNova, which employs allogeneic neural stem cells loaded with an oncolytic adenovirus specifically for the treatment of high-grade gliomas; and SuperNova, which utilizes allogeneic adipose-derived mesenchymal stem cells to deliver the tumor-selective CAL1 oncolytic vaccinia virus for advanced metastatic solid tumors. Established in 2014, Calidi Biotherapeutics operates out of San Diego, California.

Cellect Biotechnology Ltd. was an Israeli biotechnology company developing cell-selection and regenerative-medicine technologies, including its ApoGraft platform for enriching stem cells from bone marrow or other cell sources. Its products were intended primarily for clinical and research applications involving hematopoietic stem-cell transplantation and cell-based therapies.

Lisata Therapeutics, Inc. is a clinical-stage biopharmaceutical firm focused on pioneering and bringing to market cellular therapies. These treatments are designed to either reverse disease progression or facilitate the repair of damaged bodily tissues. The company's product portfolio features several notable candidates: HONEDRA, which has received SAKIGAKE designation and is presently in Phase II clinical trials for critical limb ischemia; XOWNA, currently undergoing Phase IIb testing for coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy aimed at individuals with chronic kidney disease who are not yet on dialysis. Founded in 1980 and based in Basking Ridge, New Jersey, the company was initially known as NeoStem, Inc., then rebranded as Caladrius Biosciences, Inc. in June 2015, before assuming its present identity as Lisata Therapeutics, Inc. on September 15, 2022.